Free Trial

Eli Lilly and Company $LLY Stock Purchased by Intech Investment Management LLC

Eli Lilly and Company logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Intech Investment Management increased its Eli Lilly stake by 27.8% in the third quarter, buying 24,451 shares to hold 112,366 shares valued at about $130 million. Other institutional investors also reported purchases; institutions and hedge funds own 82.53% of the stock.
  • Analyst sentiment is broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $1,416.64, with several firms recently raising their targets.
  • Lilly reported quarterly EPS of $7.48, beating estimates of $5.71, while revenue of $24.40 billion exceeded forecasts and rose 38.6% year over year.
  • MarketBeat previews the top five stocks to own by December 1st.

Intech Investment Management LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 27.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 112,366 shares of the company's stock after purchasing an additional 24,451 shares during the quarter. Eli Lilly and Company makes up 1.3% of Intech Investment Management LLC's investment portfolio, making the stock its 11th biggest holding. Intech Investment Management LLC's holdings in Eli Lilly and Company were worth $130,016,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of LLY. Coastal Bridge Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $2,959,000. Birinyi Associates Inc. increased its holdings in Eli Lilly and Company by 32.6% in the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company's stock valued at $1,689,000 after buying an additional 359 shares during the last quarter. Bernicke Wealth Management Ltd. purchased a new position in Eli Lilly and Company in the third quarter valued at $5,001,000. Mosaic Family Wealth Partners LLC raised its stake in Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock valued at $4,144,000 after buying an additional 1,430 shares in the last quarter. Finally, Trillium Asset Management LLC raised its stake in Eli Lilly and Company by 1,302.8% in the third quarter. Trillium Asset Management LLC now owns 5,036 shares of the company's stock valued at $5,831,000 after buying an additional 4,677 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a research report on Friday, October 30th. Wells Fargo & Company raised their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Scotiabank boosted their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a "sector outperform" rating in a research note on Friday, October 30th. Morgan Stanley upped their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an "overweight" rating in a report on Friday, October 30th. Finally, JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an "overweight" rating in a report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,416.64.

Read Our Latest Research Report on LLY

Trending Headlines about Eli Lilly and Company

Investors following LLY have been watching these headlines:

  • Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly's weight loss pill orforglipron
  • Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
  • Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations

Eli Lilly and Company Stock Up 0.0%

LLY opened at $1,444.05 on Monday. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,460.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The stock has a market capitalization of $1.36 trillion, a P/E ratio of 46.87, a price-to-earnings-growth ratio of 1.73 and a beta of 0.40. The business's 50-day simple moving average is $1,242.25 and its 200-day simple moving average is $1,110.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business's revenue was up 38.6% on a year-over-year basis. During the same period in the prior year, the firm earned $7.02 EPS. Analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's dividend payout ratio is presently 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company's stock.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Stories

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines